Abstract 95P
Background
The prognosis of advanced cancer including melanoma (Mel) and NSCLC has significantly improved with ICIS, leading to the emergence of new QoL issues for patients experiencing ICI-DR. The QUALICI study aimed to provide an overview of these patients’ QoL and their experiences and expectations about QoL management.
Methods
All patients with ICI-DR, defined as ICIs started for ≥2 years without subsequent treatment, were screened within 16 French sites and randomly selected to participate in this cross-sectional study. They completed questionnaires including EQ-5D-5L, Social Difficulties Inventory (SDI) and items on care and QoL management.
Results
The 234 participating patients (117 Mel; 117 NSCLC) had a mean ICI-DR of 48.8 (±14.5) months. Of them, 74.8% initiated ICI at metastatic stage and 29,5% (22.2% Mel; 36.8% NSCLC) were still treated by ICI. Most patients (NSCLC ≥62%; Mel ≥69.7%) reported no or mild issues on the 5 EQ-5D dimensions with mean Visual Analogic Scale (VAS) score of 74.8 (±19) (Mel) and 67.0 (±19.3) (NSCLC). Total SDI scores were 5.9 (±6.6) (Mel) and 10.4 (±8.5) (NSCLC) with 25% (Mel) and 50% (NSCLC) of patients presenting difficulties (score ≥10).Patients dedicated 7.7 (Mel) and 7.5 (NSCLC) hours monthly to care and assessed the burden of care at 3.1 (Mel) and 2.5 (NSCLC) on a 0-10 VAS. Two third addressed QoL issues with healthcare professionals (HP) but 21.5% could not express them as they wished. Patients prioritized closer adverse events monitoring and HP QoL training to improve QoL management (see table). Table: 95P
Patients' expectations to improve QoL management
Useful measures to improve QoL in care | NSCLC (N=117) | Melanoma (N=117) | ||
n | % | % | ||
Closer monitoring of adverse event | 65 | 58.0 | 84 | 72.4 |
QoL training for HP development | 57 | 50.9 | 61 | 55.5 |
Better coordination of the HP team | 48 | 43.6 | 55 | 50.5 |
New care method development | 47 | 42.0 | 43 | 40.6 |
Consultation dedicated to QoL | 44 | 38.9 | 47 | 41.2 |
Longer consultation | 34 | 29.8 | 44 | 38.6 |
Psychologist involvement | 33 | 29.5 | 35 | 31.0 |
Social worker support | 33 | 29.5 | 26 | 22.6 |
Tool to facilitate QoL discussions development | 30 | 27.3 | 33 | 29.7 |
Referring to discussion groups or patient associations | 29 | 25.7 | 31 | 27.0 |
Digital tool development | 22 | 19.6 | 34 | 29.6 |
Conclusions
The majority of ICI-DR patients have no or mild QoL issues, but an important proportion, especially among lung cancer patients, presents nonetheless daily life difficulties. One in five patients do not address as they wish their QoL issues with HP. Some measures prioritized by patients could improve the situation.
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Personal, Other, Family member is an employee: AstraZeneca. J. Bonastre: Financial Interests, Personal, Advisory Board, Scientific board: BMS, MSD, Janssen, Roche; Financial Interests, Institutional, Funding, Funding of the MICADO study: BMS. H. Lemasson, M. Chartier, V. Moreau-Mallet, S. Micheliza: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. N. Texier, S. Hervy, M. Coin-Bavarot: Financial Interests, Personal, Full or part-time Employment, CRO in charge of the study: Kappa Santé. C. Robert: Financial Interests, Personal, Advisory Board, Consultancy fees: BMS, Roche, Pierre Fabre, Novartis, Sanofi, MSD, Pfizer, Sun Pharma, Merck, Ultimovacs, Regeneron, Egle, Philogen, Maat Pharma; Financial Interests, Personal, Other, Steering Committee: Novartis, Regeneron, Pfizer, IO Biotech; Financial Interests, Personal, Other, IDMC: Ultimovacs; Financial Interests, Personal, Invited Speaker: Pierre Fabre, Sanofi, BMS, MSD, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract